We scan new podcasts and send you the top 5 insights daily.
Characterizing a bioreactor requires careful boundary setting because every additional variable exponentially increases the required simulation count. Adding wide continuum ranges for parameters like working volume or fluid viscosities creates an enormous operational space. Teams must strategically limit variables to discrete, sensible operating increments rather than attempting to model extreme spectrums from empty vessels to honey-like viscosities.
Christian Witz notes that biotech scientists frequently treat CFD as an intimidating tool requiring a dedicated physics or mathematics PhD. However, the real obstacle is that conventional CFD user interfaces have not been tailored to bioprocess workflows. Just as modern computer use does not require an IT technician, tailored interfaces allow routine process development scientists to employ CFD daily like Excel.
Because CFD operates strictly on physical parameters rather than biological mechanisms, a vessel needs to be fully characterized only once across 100 to 200 operational points. When switching to a new molecule, media, or cell line, the scale-up software only needs updated fluid properties such as viscosity, density, surface tension, and salt concentration, eliminating the need to re-run simulations from scratch.
Early CFD adoption in biotech faltered because limited compute power forced engineers to use geometric simplifications, such as simulating a single periodic cake slice instead of the entire reactor cylinder. Bioreactors contain massive three-dimensional wrapping flows that cannot be captured in periodic wedge models. These simplifications produced inaccurate results, leading teams to experience poor outcomes and abandon simulation for years.
By training on multi-scale data from lab, pilot, and production runs, AI can predict how parameters like mixing and oxygen transfer will change at larger volumes. This enables teams to proactively adjust processes, moving from 'hoping' a process scales to 'knowing' it will.
Modern cloud infrastructure allows teams to spin up hundreds of GPUs within seconds. Because these resources run in parallel, engineers can evaluate entire test matrices—spanning diverse stirring speeds, aeration rates, and fluid viscosities—in the exact same elapsed time that a single simulation would take, removing historical throughput bottlenecks.
The most significant breakthroughs will no longer come from traditional wet lab experiments alone. Instead, progress will be driven by the smarter application of AI and simulations, with future bioreactors being as much digital as they are physical.
The future of bioprocess development involves using AI on high-throughput data for predictive modeling. This, combined with in silico simulations (digital twins), will allow scientists to understand underlying biological mechanisms, not just identify optimal conditions, dramatically accelerating optimization.
Instead of immediately building complex models for a single problematic unit operation, start with simple linear models that connect the entire process. This holistic view reveals which parameters truly impact the final drug substance, allowing you to focus resources on building complex models only where they are most critical.
Beyond oxygen transfer, the ventilation rate (VVM)—which removes volatile compounds like CO2—is a critical scale-up parameter. A process failed to scale until the bioreactor's aeration was reduced from a standard 1 VVM to 0.5 VVM to match the shake flask's implicit rate, restoring product yield.
The challenge of scaling 3D cell cultures isn't just about building larger systems. A more fundamental problem is the inability to measure and characterize the complex 3D environment in real-time. Without effective in-process analytics to ensure quality control and process optimization, true industrial scalability remains unachievable.